Viatris Innovation Gmbh

This study tested a new oral medication called cenerimod in people with systemic lupus erythematosus (SLE). The main goal was to see if the drug could safely reduce the number of specific immune cells (lymphocytes) in the blood, which are thought to drive the disease. About 105 a…

This study tested whether a new oral medication called cenerimod could reduce disease activity in adults with moderate-to-severe lupus. Researchers compared four different doses of cenerimod against a placebo in 427 participants over six months. The main goal was to see if the dr…

This early research study tested a single dose of an experimental drug called cenerimod in 20 healthy volunteers. The goal was to check its safety and see how the body absorbs and processes it. Researchers compared results between 10 Japanese and 10 Caucasian participants to look…

This early-stage study tested a new drug called cenerimod in 97 healthy people. The main goal was to see if cenerimod affects the heart's electrical rhythm (QT interval). Researchers also checked if cenerimod changes how birth control pills work in the body and tested a method to…

This early-stage study tested how a single dose of an experimental drug called cenerimod is processed by the body in people with mild or moderate liver impairment, compared to healthy volunteers. The main goal was to understand if liver problems change how the drug moves through …

This study aimed to understand how the body processes and eliminates an experimental drug called cenerimod. Six healthy male volunteers took a single dose containing a tiny, safe amount of radioactive tracer. Researchers then carefully measured how much of the drug left the body …

This early research study tested a single dose of an experimental drug called selatogrel in healthy people. The goal was to see how the drug moves through the body and what effects it has, comparing results between 16 Japanese and 16 Caucasian volunteers. This type of study is th…

This study aimed to understand how a drug called cenerimod is processed by the body in people with severe kidney impairment. It compared 16 participants—some with healthy kidneys and some with severe kidney problems—after they took a single dose. The main goal was to check safety…